Takeda Pharma Transfers 18 Pharmaceutical Businesses: Hypera Pharma
Sao Paulo
March 10, 2020
Takeda Pharmaceutical:
Takeda Pharmaceutical Co., Ltd. announced on March 2 that its portfolio of 18 OTC / prescription pharmaceutical products (products and businesses) in seven Latin American countries (Brazil and Mexico, Argentina, Colombia, Ecuador, Panama, Peru) Agreement for transfer to Pharma (Hypera Pharma) “.
The transfer price is $ 825 million.
Future business:
The two companies have also concluded a manufacturing supply agreement.
Takeda will continue to supply the above 18 products to Ipera Pharma.
The transfer is expected to be completed in the second half of 2020.
Until then, Takeda Pharmaceutical sold the above 18 products.
Completion of the transfer requires the approval of the shareholders of both companies and the approval of the CADE (Economic Advocacy Committee) under the Antitrust Law.
Breakdown of 18 products:
Neosaldina (analgesic),
Nesina (anti-diabetic agent),
Dramin (an antiemetic),
And products that have driven sales in Takeda Pharmaceutical in seven Latin American countries.
Hypera Pharma：
Product to be transferred / Net sales in 2019 are approximately 900 million real (approximately 19.8 billion yen, 1 real = approximately 22 yen)
2019 Sales Breakdown:
83% Brazil
15% Mexico,
Others account for 2%.
-JETRO
https://www.jetro.go.jp/biznews/2020/03/13e973b308b6ff3c.html
Hypera Pharma